跳至主要内容
临床试验/CTIS2022-502633-26-00
CTIS2022-502633-26-00招募中1 期

Perioperative treatment with Tranexamic Acid (TXA) in melanoma; prognostic and treatment related impact of the plasminogen-plasmin pathway

Aarhus University Hospital0 个研究点目标入组 1,204 人开始时间: 2022年11月30日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
1,204

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • Patients: Diagnosed with invasive cutaneous melanoma (pathological stage/tumor grade higher than T2b), defined as either: Breslow thickness >1.0-2.0 mm with presence of ulceration or Breslow thickness >2.0 mm regardless of ulceration status Eligible for surgery (wide local excision and sentinel lymph node biopsy). >/=18 years of age and </=80 years of age Signed Informed Consent Form

排除标准

  • Patients: With prior history of invasive melanoma Thromboembolic events within the last 3 months Pregnancy * Active breast feeding Known allergy or hypersensitivity to TXA Known and treated epilepsia or previous seizures eGFR 0-50

研究者

发起方
Aarhus University Hospital

相似试验

Does peri-operative treatment with Tranexamic Acid... | 临床试验